

BIOBANKING: TECHNOLOGIES AND GLOBAL MARKETS



BIO084B
November 2016

Jackson Highsmith
Project Analyst

ISBN: 1-62296-391-1



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
ANALYST'S CREDENTIALS	4
METHODOLOGY AND INFORMATION SOURCES	4
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 (\$ BILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, 2015-2021 (\$ BILLIONS)</i>	7
CHAPTER 3 OVERVIEW	11
CURRENT STATE OF THE INDUSTRY	11
THE PROCESS OF BIOBANKING	12
HISTORICAL CONTEXT	12
SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS	13
<i>TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970-2015</i>	15
<i>TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2021</i>	15
<i>TABLE 3 NIH SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000-2014* (CUMULATIVE NUMBER OF NIH -SPONSORED CLINICAL TRIALS)</i>	15
Modern Biobanks	16
BIOBANKING COSTS	17
DRIVERS OF BIOBANKS GROWTH	18
RESISTORS OF BIOBANKS GROWTH	19
BIOBANKING TRENDS AND FORECAST	19
THE ROLE OF BIOBANKS IN FUTURE BIOMEDICAL DISCOVERIES	21
CHAPTER 4 OVERVIEW OF BIOBANK APPLICATIONS	25
<i>TABLE 4 GLOBAL MARKET FOR BIOBANKING BY APPLICATION, THROUGH 2021 (\$ MILLIONS)</i>	25
BIOMARKERS	25
<i>TABLE 5 SELECTED CANCER BIOBANKS IN THE U.S.</i>	26
<i>TABLE 6 GLOBAL MARKET FOR BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2021 (\$ MILLIONS/%)</i>	27
OPPORTUNITIES IN CANCER	27
<i>TABLE 7 APPLICATION OF BIOBANKS IN CANCER TREATMENT</i>	27
<i>TABLE 8 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY</i>	32
OPPORTUNITIES IN CARDIOVASCULAR DISEASE	32
<i>TABLE 9 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR</i>	33

TOPIC	PAGE NO.
OPPORTUNITIES IN NEUROLOGICAL DISEASES	35
THE BRAIN AND THE CENTRAL NERVOUS SYSTEM	35
<i>TABLE 10 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE</i>	36
OPPORTUNITIES IN IMMUNOLOGY	39
AUTOIMMUNE DISEASES	39
<i>TABLE 11 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY</i>	40
SYSTEMIC LUPUS ERYTHEMATOSUS	40
ALZHEIMER'S DISEASE	41
OTHER OPPORTUNITIES RESULTING FROM BIOBANKS	41
TARGETED THERAPEUTICS	41
DIAGNOSTIC AND PROGNOSTIC TESTS	42
Diagnostic Tests	43
Prognostic Tests	43
DRUG DEVELOPMENT	44
DISEASE ETIOLOGY	46
CHAPTER 5 CURRENT BIOBANKS WORLDWIDE	49
OVERVIEW	49
<i>TABLE 12 GLOBAL MAJOR BIOBANKS LOCATIONS, BY COUNTRY, 1998-2009</i>	49
<i>TABLE 13 TYPES OF BIOBANKS</i>	49
U.S. BIOBANKS	50
<i>TABLE 14 MAJOR NHLBI COHORT STUDIES</i>	50
<i>TABLE 15 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS</i>	50
EUROPEAN BIOBANKS	52
THE UNITED KINGDOM	52
UK Biobank	52
Licensed Biobanks in The U.K.	53
<i>TABLE 16 ESTABLISHMENTS LICENSED TO OPERATE BIOBANKS IN THE U.K., 2016</i>	53
<i>TABLE 17 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. (%)</i>	54
Biobank and Biomolecular Resource Research Infrastructure	54
<i>TABLE 18 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES (%)</i>	55
<i>TABLE 19 DISTRIBUTION OF BIOBANKS IN EU COUNTRIES</i>	56
<i>TABLE 20 OWNERSHIP OF EUROPEAN BIOBANKS (%)</i>	57
<i>TABLE 21 ACCESS TO THE EUROPEAN BIOBANK (%)</i>	57
BIOBANKS IN NORTHERN EUROPE	57
Biobanks in Denmark	59
Biobanks in the Baltic Countries	59
INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD	60
Canadian Partnership for Tomorrow Project	60
Far East Biobanks	60
China Biobank	60
The Qatar Biobank	61
Middle East Biobanks	61
CHAPTER 6 DISEASE-BASED BIOBANKS	63
GROWTH IN DISEASE-BASED BIOBANKS	63

TOPIC	PAGE NO.
<i>TABLE 22 GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY IN THE U.S., 2007-2014</i>	64
CANCER BIOBANKS	64
BIOBANKS FOR OTHER DISEASES	65
HEALTHY SAMPLE BIOBANKS	67
COLLABORATIVE NETWORKS	68
CORE UK	68
INTERNATIONAL GENOMICS CONSORTIUM	69
CANCER GENOME ATLAS	69
SEGMENT FORECAST	70
CHAPTER 7 POPULATION BASED BIOBANKS	72
INTRODUCTION	72
TYPES OF POPULATION BIOBANKS	72
COHORT STUDIES	73
<i>TABLE 23 SELECTED POPULATION-BASED COHORT BIOBANKS, 1976-2009</i>	73
FOUNDER POPULATION BIOBANKS	75
<i>TABLE 24 FOUNDER POPULATION-BASED BIOBANKS</i>	75
DECODE GENETICS	76
CARTAGENE	76
GENIZON BIOSCIENCES	76
JURILAB	76
NATIONAL POPULATION BIOBANKS	77
UK BIOBANK	77
LIFEGENE	78
ESTONIAN BIOBANK	79
LATVIAN BIOBANK	79
CANADIAN PARTNERSHIP FOR TOMORROW PROJECT	79
OTHER NATIONAL BIOBANKS	79
CHAPTER 8 FOR-PROFIT BIOBANK COMPANIES	82
CONTRACT BIOBANK AND SERVICE PROVIDERS	82
BIOMARKER DISCOVERY COMPANIES	83
PHARMACEUTICAL COLLECTIONS	84
RESEARCH COLLABORATIONS	85
CLINICAL TRIALS	86
CHAPTER 9 THE LIMITATIONS OF BIOBANKS	88
SAMPLE VARIABILITY	89
SAMPLE QUALITY	90
EFFORTS TO INCREASE HARMONIZATION	90
INITIATIVES TO IMPROVE BIOBANKS	92
CHAPTER 10 REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS	95
INTRODUCTION	95
ROLE OF THE FOOD & DRUG ADMINISTRATION	95
CURRENT REGULATORY FRAMEWORK	96

TOPIC	PAGE NO.
INFORMED CONSENT	97
WITHDRAWAL AND OWNERSHIP	99
CONFIDENTIALITY	99
COMMERCIALIZATION	100
FDA GUIDELINES FOR BIOMARKER APPLICATIONS	100
<i>TABLE 25 FDA GUIDELINES FOR BIOMARKER APPLICATIONS</i>	101
EUROPEAN MEDICINES AGENCY	102
REGULATORY IMPACT ON DRUG SAFETY	102
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING	103
APPROVED PATENT ANALYSIS	103
<i>TABLE 26 GLOBAL ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS BY REGION, THROUGH 2016</i>	103
COMPETITIVE LANDSCAPE	103
LATE STAGE CLINICAL TRIALS: COMPETITIVE POSITIONING	104
<i>TABLE 27 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2021 (\$ MILLIONS)</i>	104
<i>TABLE 28 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY</i>	105
<i>TABLE 29 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN</i>	106
ETHICAL CONSIDERATIONS	107
SUMMARY	107
REGULATORY IMPLICATIONS	108
CHAPTER 11 BIOBANK MARKETS FORECAST BY SEGMENT AND REGION	110
SUMMARY	110
<i>TABLE 30 GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 (\$ BILLIONS)</i>	110
GEOGRAPHIC MIX	111
<i>TABLE 31 GLOBAL MARKET SHARE OF BIOBANKS BY REGION, 2015-2021 (%)</i>	111
CHAPTER 12 DETAILED DESCRIPTION OF THE USE OF BIOMARKERS	113
COLORECTAL CANCER	113
CETUXIMAB	113
PANITUMUMAB	114
ELESCLOMOL	115
HERCEPTIN	116
OTHER PREDICTIVE TESTS	116
<i>TABLE 32 CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY</i>	117
BREAST CANCER	118
MAMMAPRINT	119
<i>TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER, 2007-2009</i>	119
ONCOTYPE DX	120
TEST ADOPTION	121
OTHER PROGNOSTIC TESTS	123
HORMONAL THERAPIES	124
TAXANES/ANTHRACYCLINES	125
TRIPLE NEGATIVE BREAST CANCER	126

TOPIC	PAGE NO.
OTHER NOVEL BIOMARKERS	126
LUNG CANCER	127
INTRODUCTION	127
PREDICTIVE TESTS	128
<i>TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER, 2006-2014</i>	128
GEFITINIB	129
ERLOTINIB	130
OTHER PREDICTIVE TESTS	131
NOVEL THERAPIES	132
PROSTATE CANCER	133
OVARIAN CANCER	135
MALIGNANT MELANOMA	136
<i>TABLE 35 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA, 2006-2016</i>	137
CARDIOVASCULAR	138
<i>TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR, 2010-2014</i>	140
CENTRAL NERVOUS SYSTEM	141
<i>TABLE 37 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE, 2010-2013</i>	142
<i>TABLE 38 BIOMARKERS/TEST FOR OTHER NEUROLOGICAL DISEASES, 2008-2009</i>	143
IMMUNOLOGY- AUTOIMMUNE DISEASES	143
<i>TABLE 39 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY, 2009-2014</i>	144
IMMUNOLOGY	144
BENLYSTA: HUMAN GENOME SCIENCES	144
EXPEDITION AND IDENTITY ALZHEIMER'S TRIAL: ELI LILLY	145
CHAPTER 13 COMPANY ANALYSIS	147
ABBOTT LABORATORIES INC.	147
COMPANY OVERVIEW	147
PRODUCTS AND SERVICES	147
<i>TABLE 40 ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	147
COMPANY STRATEGY	148
AFFYMETRIX, INC.	148
COMPANY OVERVIEW	148
PRODUCTS AND SERVICES	148
COMPANY STRATEGY	149
ASTERAND PLC	149
COMPANY OVERVIEW	149
PRODUCTS AND SERVICES	150
<i>TABLE 41 ASTERAND PRODUCTS OVERVIEW BY TYPE OF BIOBANK</i>	150
COMPANY STRATEGY	150
ASTRAZENECA LTD	150
COMPANY OVERVIEW	150
PRODUCTS AND SERVICES	150
<i>TABLE 42 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	151

TOPIC	PAGE NO.
COMPANY STRATEGY	151
BAYER SCHERING PHARMA AG	151
COMPANY OVERVIEW	152
PRODUCTS AND SERVICES	152
COMPANY STRATEGY	152
BIOCHAIN-GENOMICS	153
COMPANY OVERVIEW	153
PRODUCTS AND SERVICES	153
<i>TABLE 43 BIOCHAIN-GENOMICS' PRODUCTS OVERVIEW BY TYPE OF BIOBANK</i>	153
COMPANY STRATEGY	153
BIOSTORAGE TECHNOLOGIES, INC.	154
COMPANY OVERVIEW	154
PRODUCTS AND SERVICES	154
<i>TABLE 44 BIOSTORAGE TECHNOLOGIES' PRODUCTS OVERVIEW BY TYPE OF BIOBANK</i>	154
COMPANY STRATEGY	155
BOEHRINGER INGELHEIM GMBH	155
COMPANY OVERVIEW	155
PRODUCTS AND SERVICES	155
COMPANY STRATEGY	155
BRISTOL-MYERS SQUIBB CO	156
COMPANY OVERVIEW	156
PRODUCTS AND SERVICES	156
<i>TABLE 45 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	156
COMPANY STRATEGY	157
DAIICHI SANKYO COMPANY, LTD	157
COMPANY OVERVIEW	157
PRODUCTS AND SERVICES	157
COMPANY STRATEGY	158
ELI LILLY AND COMPANY	158
COMPANY OVERVIEW	159
PRODUCTS AND SERVICES	159
<i>TABLE 46 ELI LILLY REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	159
COMPANY STRATEGY	160
EXIQON LIFE SCIENCES	160
COMPANY OVERVIEW	160
PRODUCTS AND SERVICES	160
<i>TABLE 47 EXIQON PRODUCTS OVERVIEW BY TYPE OF BIOBANK</i>	160
COMPANY STRATEGY	161
GLAXOSMITHKLINE	161
COMPANY OVERVIEW	161
PRODUCTS AND SERVICES	162
<i>TABLE 48 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	162
COMPANY STRATEGY	162
JOHNSON & JOHNSON LTD	163
COMPANY OVERVIEW	163
PRODUCTS AND SERVICES	163
COMPANY STRATEGY	163

TOPIC	PAGE NO.
MILLENNIUM PHARMACEUTICALS	164
COMPANY OVERVIEW	164
PRODUCTS AND SERVICES	164
<i>TABLE 49 MILLENNIUM PRODUCTS OVERVIEW BY TYPE OF BIOBANK</i>	164
COMPANY STRATEGY	164
MERCK & CO.	165
COMPANY OVERVIEW	165
PRODUCTS AND SERVICES	165
<i>TABLE 50 MERCK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	166
COMPANY STRATEGY	166
NOVARTIS AG	166
COMPANY OVERVIEW	167
PRODUCTS AND SERVICES	167
<i>TABLE 51 NOVARTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	167
COMPANY STRATEGY	167
PFIZER INC	168
COMPANY OVERVIEW	168
PRODUCTS AND SERVICES	168
<i>TABLE 52 PFIZER REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	168
COMPANY STRATEGY	169
F. HOFFMAN-LA ROCHE AG	169
COMPANY OVERVIEW	169
PRODUCTS AND SERVICES	169
<i>TABLE 53 ROCHE REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	170
COMPANY STRATEGY	170
SANOFI-AVENTIS	170
COMPANY OVERVIEW	171
PRODUCTS AND SERVICES	171
<i>TABLE 54 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS</i>	172
COMPANY STRATEGY	172
SCIPAC	173
COMPANY OVERVIEW	173
PRODUCTS AND SERVICES	173
<i>TABLE 55 SCIPAC PRODUCTS OVERVIEW BY TYPE OF BIOBANK</i>	173
COMPANY STRATEGY	173
TAKEDA PHARMACEUTICALS LTD	174
COMPANY OVERVIEW	174
PRODUCTS AND SERVICES	174
COMPANY STRATEGY	174
TEVA PHARMACEUTICAL INDUSTRIES LTD.	175
COMPANY OVERVIEW	175
PRODUCTS AND SERVICES	175
COMPANY STRATEGY	176

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 (\$ BILLIONS)	7
TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970-2015	15
TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2021	15
TABLE 3 NIH SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000-2014* (CUMULATIVE NUMBER OF NIH -SPONSORED CLINICAL TRIALS)	15
TABLE 4 GLOBAL MARKET FOR BIOBANKING BY APPLICATION, THROUGH 2021 (\$ MILLIONS)	25
TABLE 5 SELECTED CANCER BIOBANKS IN THE U.S.	26
TABLE 6 GLOBAL MARKET FOR BIOMARKERS IN LATE STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2021 (\$ MILLIONS/%)	27
TABLE 7 APPLICATION OF BIOBANKS IN CANCER TREATMENT	27
TABLE 8 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: ONCOLOGY	32
TABLE 9 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR	33
TABLE 10 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE	36
TABLE 11 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY	40
TABLE 12 GLOBAL MAJOR BIOBANKS LOCATIONS, BY COUNTRY, 1998-2009	49
TABLE 13 TYPES OF BIOBANKS	49
TABLE 14 MAJOR NHLBI COHORT STUDIES	50
TABLE 15 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS	50
TABLE 16 ESTABLISHMENTS LICENSED TO OPERATE BIOBANKS IN THE U.K., 2016	53
TABLE 17 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. (%)	54
TABLE 18 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES (%)	55
TABLE 19 DISTRIBUTION OF BIOBANKS IN EU COUNTRIES	56
TABLE 20 OWNERSHIP OF EUROPEAN BIOBANKS (%)	57
TABLE 21 ACCESS TO THE EUROPEAN BIOBANK (%)	57
TABLE 22 GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY IN THE U.S., 2007-2014	64
TABLE 23 SELECTED POPULATION-BASED COHORT BIOBANKS, 1976-2009	73
TABLE 24 FOUNDER POPULATION-BASED BIOBANKS	75
TABLE 25 FDA GUIDELINES FOR BIOMARKER APPLICATIONS	101
TABLE 26 GLOBAL ANNUAL PATENTS FILED AND APPROVED WITH BIOMARKER CLAIMS BY REGION, THROUGH 2016	103
TABLE 27 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS BY SERVICES AND PRODUCTS, THROUGH 2021 (\$ MILLIONS)	104
TABLE 28 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER DELIVERY	105
TABLE 29 REPRESENTATIVE LIST OF APPROVED BIOMARKER PATENTS IN THE U.S., EUROPE AND JAPAN	106
TABLE 30 GLOBAL MARKET FOR BIOBANKS BY SEGMENT, THROUGH 2021 (\$ BILLIONS)	110
TABLE 31 GLOBAL MARKET SHARE OF BIOBANKS BY REGION, 2015-2021 (%)	111
TABLE 32 CURRENT ACTIVE BIOMARKER TRIALS ONGOING: ONCOLOGY	117
TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: BREAST CANCER, 2007-2009	119
TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: LUNG CANCER, 2006-2014	128

TABLE HEADING	PAGE NO.
TABLE 35 REPRESENTATIVE ACTIVE BIOMARKER TRIALS ONGOING: MALIGNANT MELANOMA, 2006-2016	137
TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CARDIOVASCULAR, 2010-2014	140
TABLE 37 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS DISEASE, 2010-2013	142
TABLE 38 BIOMARKERS/TEST FOR OTHER NEUROLOGICAL DISEASES, 2008-2009	143
TABLE 39 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: IMMUNOLOGY, 2009-2014	144
TABLE 40 ABBOTT REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	147
TABLE 41 ASTERAND PRODUCTS OVERVIEW BY TYPE OF BIOBANK	150
TABLE 42 ASTRAZENECA REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	151
TABLE 43 BIOCHAIN-GENOMICS' PRODUCTS OVERVIEW BY TYPE OF BIOBANK	153
TABLE 44 BIOSTORAGE TECHNOLOGIES' PRODUCTS OVERVIEW BY TYPE OF BIOBANK	154
TABLE 45 BMS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	156
TABLE 46 ELI LILLY REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	159
TABLE 47 EXIQON PRODUCTS OVERVIEW BY TYPE OF BIOBANK	160
TABLE 48 GSK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	162
TABLE 49 MILLENNIUM PRODUCTS OVERVIEW BY TYPE OF BIOBANK	164
TABLE 50 MERCK REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	166
TABLE 51 NOVARTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	167
TABLE 52 PFIZER REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	168
TABLE 53 ROCHE REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	170
TABLE 54 SANOFI-AVENTIS REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS	172
TABLE 55 SCIPAC PRODUCTS OVERVIEW BY TYPE OF BIOBANK	173

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR BIOBANKS BY SEGMENT, 2015-2021 (\$ BILLIONS)	7